Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan Capital

Chardan Capital reiterated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report sent to investors on Monday morning, Benzinga reports. Chardan Capital currently has a $14.00 price objective on the stock.

Coya Therapeutics Trading Down 3.6 %

Shares of Coya Therapeutics stock opened at $8.72 on Monday. The company has a fifty day moving average price of $9.22 and a 200 day moving average price of $7.21. Coya Therapeutics has a twelve month low of $3.21 and a twelve month high of $10.69. The stock has a market cap of $127.31 million, a price-to-earnings ratio of -11.18 and a beta of 0.80.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Tuesday, March 19th. The company reported $0.15 earnings per share for the quarter. The company had revenue of $6.00 million during the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Greenlight Capital Inc. increased its stake in Coya Therapeutics by 172.2% during the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock worth $9,441,000 after buying an additional 805,959 shares during the period. AIGH Capital Management LLC grew its stake in shares of Coya Therapeutics by 92.6% during the fourth quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock valued at $7,381,000 after acquiring an additional 496,183 shares in the last quarter. Finally, CM Management LLC increased its position in shares of Coya Therapeutics by 66.7% during the third quarter. CM Management LLC now owns 100,000 shares of the company’s stock worth $384,000 after acquiring an additional 40,000 shares during the last quarter. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.